|
Age, per 1 year
|
1.007
|
0.985–1.031
|
0.511
|
|
Male
|
0.990
|
0.489–2.005
|
0.978
|
|
Body mass index, per 1 kg/m2
|
0.943
|
0.872–1.015
|
1.060
|
|
STE-ACS
|
0.831
|
0.474–1.456
|
0.559
|
|
Killip class > 1
|
1.028
|
0.520–2.037
|
0.935
|
|
Culprit LAD
|
0.982
|
0.579–1.666
|
0.947
|
|
Culprit LCx
|
0.488
|
0.169–1.411
|
0.177
|
|
Cilprit RCA
|
1.300
|
0.757–2.234
|
0.341
|
|
Multivessel disease
|
0.411
|
0.240–0.704
|
0.001
|
|
GRACE score > 140
|
1.283
|
0.756–2.178
|
0.355
|
|
Hypertension
|
0.838
|
0.492–1.429
|
0.516
|
|
Hypercholesterolemia
|
1.053
|
0.614–1.804
|
0.852
|
|
Systolic blood pressure on admission, per 1 mmHg
|
0.995
|
0.988–1.002
|
0.214
|
|
Heart rate on admission, per 1 bpm
|
1.003
|
0.990–1.017
|
0.638
|
|
Cre on admission, per 1 mg/dl
|
1.598
|
0.909–2.914
|
0.098
|
|
eGFR on admission, per 1%
|
0.996
|
0.982–1.008
|
0.522
|
|
Peak level of CPK, per 1 IU/l
|
1.000
|
0.999–1.000
|
0.534
|
|
BNP during stable phase, per 1 pg/ml
|
1.001
|
1.000–1.003
|
0.013
|
|
hs-CRP during stable phase > 0.1355 mg/dl
|
2.278
|
1.325–3.915
|
0.002
|
|
LDL cholesterol, per 1 mg/dl
|
1.000
|
0.993–1.007
|
0.994
|
|
HDL cholesterol, per 1 mg/dl
|
0.972
|
0.946–0.996
|
0.030
|
|
Triglycerides, per 1 mg/dl
|
0.999
|
0.997–1.001
|
0.571
|
|
ACE-I or ARB use at discharge
|
0.737
|
0.396–1.374
|
0.336
|
|
β-blocker use at discharge
|
1.127
|
0.642–1.979
|
0.676
|
|
Statin use at discharge
|
0.596
|
0.188–1.888
|
0.374
|
|
Diabetes mellitus
|
1.251
|
0.726–2.158
|
0.420
|
|
Impaired glucose tolerance
|
1.218
|
0.719–2.063
|
0.463
|
|
Normal glucose tolerance
|
0.510
|
0.242–1.074
|
0.072
|
|
Glucose on admission > 180 mg/dl
|
2.238
|
1.286–3.893
|
0.004
|
|
Hemoglobin A1c level, %
|
1.267
|
1.030–1.546
|
0.021
|
|
High MAGE
|
2.347
|
1.378–3.998
|
0.001
|
|
Ave, mg/dl
|
1.001
|
0.998–1.013
|
0.155
|
|
SD
|
1.016
|
0.994–1.038
|
0.141
|
|
CV
|
1.020
|
0.982–1.058
|
0.293
|
